Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation
MPTP Mouse Models of Parkinson's Disease: An Update
Article type: Review Article
Authors: Meredith, Gloria E. | Rademacher, David J.
Affiliations: Department of Pharmaceutical Sciences, College of Pharmacy, Rosalind Franklin University of Medicine and Science, IL, USA | Department of Cellular and Molecular Pharmacology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, IL, USA
Note:  Correspondence to: Gloria E. Meredith, Department of Pharmaceutical Sciences, Rosalind Franklin University of Medicine and Science, 3333 Green Bay Road, North Chicago, IL 60064, USA. Tel.: +1 847 578 3270; Fax: +1 847 775 6586; E-mail: [email protected]
Keywords: substantia nigra, dopamine, C57/BL mouse, grid test, hydropyridine, open field, rotarod
Journal: Journal of Parkinson's Disease, vol. 1, no. 1, pp. 19-33, 2011
Among the most widely used models of Parkinson's disease (PD) are those that employ toxins, especially 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Depending on the protocol used, MPTP yields large variations in nigral cell loss, striatal dopamine loss and behavioral deficits. Motor deficits do not fully replicate those seen in PD. Nonetheless, MPTP mouse models mimic many aspects of the disease and are therefore important tools for understanding PD. In this review, we will discuss the ability of MPTP mouse models to replicate the pathophysiology of PD, the mechanisms of MPTP-induced neurotoxicity, strain differences in susceptibility to MPTP, and the models' roles in testing therapeutic approaches.